Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats

World Journal of Gastroenterology

Volumn 9, Issue 11, 2003, Pages 2533-2538

  Dong, Wei Guo ^a   Liu, Shao Ping ^a   Yu, Bao Ping ^a   Wu, Dong Fang ^a   Luo, He Sheng ^a   Yu, Jie Ping ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CYCLOOXYGENASE 2; ENEMA; FERULIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MESALAZINE; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RAT; TISSUE LEVEL; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 0344467399     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i11.2533     Document Type: Article

References (45)

1. Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: Recent advances in the immunotherapy of inflammatory bowel disease. J Gastroenterol 2003; 38(Suppl 15): 36-42
2. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002; 33: 311-322
3. Lakatos L. Immunology of inflammatory bowel diseases. Acta Physiol Hung 2000; 87: 355-372
4. Travis S. Recent advances in immunomodulation in the treatment of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003; 15: 215-218
5. Tuvlin JA, Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs 2003; 12: 483-490
6. Goh J, O'Morain CA. Nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 307-320
7. Hanauer SB. Update on medical management of inflammatory bowel disease: Ulcerative colitis. Rev Gastroenterol Disord 2001; 1: 169-176
8. Kane SV. Novel therapies in the treatment of ulcerative colitis. Expert Opin Investig Drugs 2001; 10: 1223-1229
9. Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenterol 2000; 6: 483-489
10. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: Current status and future directions. Am J Gastroenterol 2003; 98: 530-537
11. Holtmann MH, Galle PR, Neurath MF. Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther 2001; 1: 455-466
12. Rampton DS. Management of difficult inflammatory bowel disease: Where are we now? World J Gastroenterol 2000; 6: 315-323
13. Kikuzaki H, Hisamoto M, Hirose K, Akiyama K, Taniguchi H. Antioxidant properties of ferulic acid and its related compounds. J Agric Food Chem 2002; 50: 2161-2168
14. Ogiwara T, Satoh K, Kadoma Y, Murakami Y, Unten S, Atsumi T, Sakagami H, Fujisawa S. Radical scavenging activity and cytotoxicity of ferulic acid. Anticancer Res 2002; 22: 2711-2717
15. Zhang ZH, Yu SZ, Li GS, Zhao BT. Influence of sodium ferulate on human netrophil-derived oxygen metabolites. Zhongguo Yaolixue Tongbao 2001; 17: 515-517
16. Li YQ, Zhang JS, Cai HW. Influence of sodium ferulate on MDA, SOD, ET and NO during myocardial ischemia and reperfusion injury. Zhonghua Mazuixue Zazhi 1998; 18: 688-690
17. Xu LN, Yu WG, Tian JY, Liu QY. Effect of sodium ferulate on arachidonic acid metabolism. Yaoxue Xuebao 1990; 25: 412-416
18. 2 synthetase. Zhongguo Yaoli Xuebao 1988; 9: 430-433
19. Millar AD, Rampton DS, Chandler CL, Claxson AW, Blades S, Coumbe A, Panetta J, Morris CJ, Blake DR. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 1996; 39: 407-415
20. Deng CH, Xia B, Chen DJ, Zhou Y, Gong TT, Guao ZQ. The mucosa protective effects of superoxide dismutase on rats colitis induced by acetic acid. Zhongguo Bingli Shengli Zazhi 1994; 10: 23-25
21. 2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol 1995; 90: 614-620
22. 2, receptor antagonist in an animal model of inflammatory bowel disease. Digestion 1997; 58: 476-478
23. Linnoila RI, Jensen SM, Steinberg SM, Mulshine JL, Eggleston JC, Gazdar AF. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol 1992; 97: 233-243
24. Li L, Wang ZL, Ke JT, Zhang M, Shao JF, Zhong CN. Select animal models for experimental colitis model. Shijie Huaren Xiaohua Zazhi 2001; 9: 584-585
25. Krieglstein CF, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G, Grisham MB, Ross CR, Granger DN. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: Divergent roles of superoxide and nitric oxide. J Exp Med 2001; 194: 1207-1218
26. Zhou JF, Cai D, Zhu YG, Yang JL, Peng CH, Yu YH. A study on relationship of nitric oxide, oxidation, peroxidation, lipoperoxidation with chronic chole-cystitis. World J Gastroenterol 2000; 6: 501-507
27. Wang QG, He LY, Chen YW, Hu SL. Enzymohistochemical study on burn effect on rat intestinal NOS. World J Gastroenterol 2000; 6: 421-423
28. Jourd'heuil D, Morise Z, Conner EM, Grisham MB. Oxidants, transcription factors, and intestinal inflammation. J Clin Gastroenterol 1997; 25(Suppl 1): S61-S672
29. Banan A, Fields JZ, Zhang Y, Keshavarzian A. iNOS upregulation mediates oxidant-induced disruption of F-actin and barrier of intestinal monolayers. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1234-G1246
30. Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 2002; 23: 529-536
31. McCowen KC, Ling PR, Bistrian BR. Arachidonic acid concentrations in patients with Crohn disease. Am J Clin Nutr 2000; 71: 1008
32. Carty E, Macey M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: Anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 807-817
33. Karmeli F, Cohen P, Rachmilewitz D. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 2000; 12: 223-231
34. Kankuri E, Vaali K, Korpela R, Paakkari I, Vapaatalo H, Moilanen E. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 2001; 25: 301-310
35. Wu JX, Xu JY, Yuan YZ. Effect of emodin and sandostatin on metabolism of eicosanoids in acute necrotizing pancreatitis. World J Gastroenterol 2000; 6: 293-294
36. Shi XZ, Lindholm PF, Sarna SK. NF-kappa B activation by oxidative stress and inflammation suppresses contractility in colonic circular smooth muscle cells. Gastroenterology 2003; 124: 1369-1380
37. Gan H, Ouyang Q, Chen Y, Xia Q. Activation of nuclear factor-kappa B and effects of anti-inflammatory treatment thereon in intestinal mucosa of patients with ulcerative colitis. Zhonghua Yixue Zazhi 2002; 82: 384-388
38. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001; 480-481: 243-268
39. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-142
40. Jobin C, Sartor RB. NF-kappa B signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000; 6: 206-213
41. Wulczyn FG, Krappmann D, Scheidereit C The NF-κB/Rel and IkB gene families: Mediators of immune response and inflammation. J Mol Med 1996; 74: 749-769
42. Sahnoun Z, Jamoussi K, Zeghal KM. Free radicals and antioxidants: Physiology, human pathology and therapeutic aspects (part II). Therapie 1998; 53: 315-339
43. Petranka J, Wright G, Forbes RA, Murphy E. Elevated calcium in preneoplastic cells activates NF-kappa B and confers resistance to apoptosis. J Biol Chem 2001; 276: 37102-37108
44. Potoka DA, Upperman JS, Nadler EP, Wong CT, Zhou X, Zhang XR, Ford HR. NF-kappa B inhibition enhances peroxynitrite-induced enterocyte apoptosis. J Surg Res 2002; 106: 7-14
45. Teresa Bengoechea-Alonso M, Pelacho B, Oses-Prieto JA, Santiago E, Lopez-Moratalla N, Lopez-Zabalza MJ. Regulation of NF-kappa B activation by protein phosphatase 2B and NO, via protein kinase A activity, in human monocytes. Nitric Oxide 2003; 8: 65-74